Skip to content
Baltimore News Journal – Lifestyle
Author:
Rezolute, Inc.
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
November 13, 2026
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
November 13, 2026
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
November 5, 2026
Rezolute to Participate in Upcoming Investor Conferences
November 2, 2026
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
October 14, 2026
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
October 5, 2026
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
September 24, 2026
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
September 9, 2026
Rezolute to Participate in Upcoming Investor Conferences
September 2, 2026
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 21, 2026
1
2
Next Page
→